1Q Revenues: $9.3 billion (-2%)
1Q Earnings: $1.7 billion (-26%)
Comments: Lantus sales were up 13% to $1.3 billion in the quarter. Lovenox sales were down 27% to $821.9 million; Taxotere sales were down 32% to $538.5 million; and Plavix sales were down 14% to $682.3 million, due to generic competition, as well as austerity measures in EU and healthcare reform in the U.S. Eloxatin sales were up 173% to $265.0 million and Multaq sales were up 154% to $88.8 million. Results include a non-recurring charge of $458.2 million related to Merial assets. Revenues were also impacted by declining A/H1N1 sales compared to 1Q10.